Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07421076 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Grid eXplore Mapping Study

StatusRecruiting
PhaseNot applicable
Started2026-04-02
View on ClinicalTrials.gov ↗

Amendment history

2026-06-29
Study Status, Contacts/Locations v4
Study sitesdetails revised at 2 of 5 sites
2026-05-04
Study Status, Contacts/Locations v3
Study sitesdetails revised at 2 of 5 sites
2026-04-15
Study Status v2
Re-verified, no change to tracked fields
2026-04-06
Study Status, Contacts/Locations v1
Recruitment opened
Primary completion moved earlier: 2027-02-07 → 2026-11-07
Completion moved earlier: 2028-01-31 → 2027-10-31
Start dateestimated 2026-03-31→confirmed 2026-04-02
Study sitesdetails revised at 5 of 5 sites
2026-02-12
Original filing
The purpose of the trial is to find out if the Grid X Mapping Catheter and EnSite X EP System with EnSite X Software v3.1.1, the devices that are being studied, are safe and effective in treating Chinese patients who have atrial fibrillation. Participants will receive a procedure called catheter mapping and ablation to treat their abnormal heart rhythms and are required to complete 4 follow-up visits at 7 days, 3 months, 6 months and 12 months after the procedure for checkups and tests.
Trial Details
NCT Number NCT07421076
Lead Sponsor Abbott Medical Devices
Conditions Paroxysmal Atrial Fibrillation (PAF)
Enrollment 200 participants
Start Date 2026-04-02
Primary Completion 2026-11-07 (estimated)
Study Completion 2027-10-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-01